UK markets closed

Ultimovacs ASA (ULTIO.OL)

Oslo - Oslo Delayed price. Currency in NOK
Add to watchlist
68.000.00 (0.00%)
At close: 03:44PM CEST
Full screen
Previous close68.00
Open68.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range68.00 - 68.00
52-week range68.00 - 68.00
Volume400
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine

    Comprehensive characterization of phase I UV1-checkpoint inhibitor combination trialClinical responses seen in patients with favored and less favored baseline characteristicsT cell activation observed post-treatment in tumors of responding patients Oslo, September 12, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for the treatment of cancer, announced today the publication of data from its phase I melanoma trial in Journal of Translational

  • Globe Newswire

    Ultimovacs ASA: New share capital registered

    Oslo, 9 September 2022, Ultimovacs ASA (the "Company") refers to the announcement published on 5 September 2022 regarding the issuance of new shares in connection with the Company's employee incentive program. The share capital increase related to the share issue of 44,000 new shares has been registered in the Norwegian Register of Business Enterprises, and the Company's new share capital is NOK 3,426,576.10, divided into 34,265,761 shares, each with a par value of NOK 0.10. For further informat

  • Globe Newswire

    Ultimovacs ASA: Mandatory notification of trade by primary insider

    Oslo, 05 September 2022, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 2,000 shares in the company at an average price of NOK 67.10 per share. Following this transaction, Carlos de Sousa and closely related parties hold 20,056 shares and 416,035 share options in Ultimovacs ASA. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act. At